Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 496 to 510 of 1308 results for social care

  1. Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]

    In development Reference number: GID-TA11116 Expected publication date:  11 November 2026

  2. Filgotinib for treating axial spondyloarthritis [ID6594]

    In development Reference number: GID-TA11776 Expected publication date: TBC

  3. Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]

    In development Reference number: GID-TA11414 Expected publication date: TBC

  4. Intrathecal onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [ID6556]

    In development Reference number: GID-TA11733 Expected publication date:  26 August 2026

  5. Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 21 July 2026.

  6. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]

    In development Reference number: GID-HST10063 Expected publication date: TBC

  7. Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]

    In development Reference number: GID-TA11454 Expected publication date: TBC

  8. Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]

    In development Reference number: GID-TA11096 Expected publication date:  03 September 2026

  9. Fractures (non-complex): assessment and management (NG38)

    This guideline covers assessing and managing non-complex fractures that can be treated in the emergency department or orthopaedic clinic. It aims to improve practice so that people with fractures receive the care that they need without unnecessary tests and treatments.

  10. Research to access pathway for investigational drugs for COVID-19 (RAPID C-19)

    RAPID C-19’s role in reviewing potential COVID-19 treatments has now ended because we have moved back to routine commissioning arrangements for these treatments.

  11. Cancer of the upper aerodigestive tract: assessment and management in people aged 16 or over (NG36)

    This guideline covers assessing and managing cancers of the upper aerodigestive tract in people aged 16 or over. These are cancers of the airways of the head and neck, including the mouth, throat, larynx (voicebox) and sinuses. The guideline aims to reduce variation in practice and improve survival.

  12. What type of training and awareness-raising can improve how health and social care practitioners: - promote vitamin D supplements among at-risk groups - improve the local population's awareness of, and attitudes towards, vitamin D supplements - uptake of vitamin D supplements?

    What type of training and awareness-raising can improve how health and social care practitioners: - promote vitamin D supplements among...

  13. About NICE guidelines

    NICE guidelines are evidence-based recommendations for health and care in England and Wales.

  14. Your role as a NICE committee member

    member From GPs, nurses and social workers, to pharmacists, physiotherapists and patients, your voice has the power to transform...

  15. Your role as a NICE committee member

    member From GPs, nurses and social workers, to pharmacists, physiotherapists and patients, your voice has the power to transform...